ライフサイエンスコーパス: cytokeratin

1 mors were positive for the epithelial marker cytokeratin.

2 e ultra-staged with immunohistochemistry for cytokeratin.

3 n (EMA), Ber-EP4, AE1, AE3, and 8 individual cytokeratins.

4 e expression of E-cadherin, desmoplakin, and cytokeratins.

5 stromal Bmp4, epithelial Sox9, and columnar cytokeratins.

6 nue expression of Thy-1 and begin to express cytokeratins.

7 ng membrane proteins, secreted proteins, and cytokeratins.

8 in, epithelial membrane antigen, and various cytokeratins.

9 rotein that facilitates MPO internalization, cytokeratin 1 (CK1), identified using affinity chromatog

10 s a bifunctional protein that binds to human cytokeratin 10 (K10) and fibrinogen (Fg).

11 Cytokeratin 10 (K10) and loricrin expression were then e

12 ression of key structural proteins including cytokeratin-10 and loricrin, resulting in increased kera

13 corneal epithelial cells and the absence of cytokeratin 12 (K12) expression featured Cited2 deficien

14 l surface (conjunctivalized corneal surface: cytokeratin 12 [cK12]-negative and mucin 1 [MUC1]-positi

15 cal microscopy and impression cytology (PAS, cytokeratin 12, and cytokeratin 19) staining were perfor

16 els of mature cornea epithelial cell marker, cytokeratin 12.

17 pithelia that express nestin: one expressing cytokeratin 14 (CK14) and DeltaN-p63 and another express

18 d of stem cells, which were characterized by cytokeratin 14 (CK14) staining and enhanced tumor sphere

19 Cytokeratin 14 (CK14) was examined by immunohistochemist

20 binase (CreER(tam)) under the control of the cytokeratin 14 (K14) promoter (K14-CreER(tam)) and mice

21 IHC confirmed increased cytokeratin 14 expression in female bladders and additio

22 dings and revealed a significant increase in cytokeratin 14 expression in the urothelium of the femal

23 20(OH)D3 stimulated involucrin and inhibited cytokeratin 14 expression.

24 tionship between loss of FOXA1 and increased cytokeratin 14 expression.

25 Co-localization studies with cytokeratin 14 indicated that KCNQ1 is also expressed in

26 umor cells expressing markers of basal (p63, cytokeratin 14) and luminal (cytokeratin 8 and androgen

27 owed thinning of skin epithelium and loss of cytokeratin 14, an early marker of skin differentiation.

28 uently stained for pimonidazole, sirius red, cytokeratin 14, and hematoxylin-eosin for quantitative a

29 microtubules in mesenchymal cells increased cytokeratin 14-positive (K14+) progenitors and their dif

30 ders and additionally revealed enrichment of cytokeratin 14-positive basal cells in the hyperplastic

31 xpression of basal epithelial genes, such as cytokeratin-14 (K14) and p63.

32 We show that formation of the actin/cytokeratin/14-3-3sigma complex and cellular migration a

33 skin were located in the area highlighted by cytokeratin 15 staining in vivo.

34 fiber (OF) immunosensor for the detection of cytokeratin 17 (CK17), a biomarker of interest for lung

35 AIRE with the intermediate filament protein cytokeratin 17 (K17) in the THP-1 monocyte cell line.

36 We have recently demonstrated that plasma cytokeratin 18 (CK-18) fragment levels correlate with th

37 necrosis in serum was quantified using serum cytokeratin 18 (CK18) M30 and M65 enzyme-linked immunoso

38 ormal unperturbed RPE are immunoreactive for cytokeratin 18 and negative for cytokeratin 19, vimentin

39 ated with increased apoptosis (caspase 3 and cytokeratin 18 cleavage) in excised tumors.

40 of lactate dehydrogenase and caspase-cleaved cytokeratin 18 in the perfused medium.

41 zyme-linked immunosorbent assays for various cytokeratin 18 products (eg, M65, cell death, M30, and a

42 Notably, mice expressing hDPP4 with the cytokeratin 18 promoter developed progressive, uniformly

43 trol of the surfactant protein C promoter or cytokeratin 18 promoter that are susceptible to infectio

44 Elevated total cytokeratin 18 suggested the presence of necrotic cell d

45 , hepatocyte nuclear factor 4alpha, albumin, cytokeratin 18, and cytochrome P450 3A.

46 epithelial phenotype, expressing E-cadherin, cytokeratin 18, and desmin.

47 rum transaminases were normal in TASH, total cytokeratin 18, but not the caspase-cleaved fragment, wa

48 rly reactive RPE (7 days in culture) express cytokeratin 18, cytokeratin 19, and vimentin.

49 markers of colonic epithelial cells such as cytokeratin 18, zonula occludens-1, mucins-1 and -2, ant

50 strogen, and progesterone receptor-positive, cytokeratin 18-positive (ER(+)PR(+)CK18(+)) subtype, and

51 claudin 3, 4, and 7 and the luminal marker, cytokeratin 18.

52 ation of fibrosis-associated markers such as cytokeratins 18 and 19 and annexin 2, as determined both

53 say (ELISA), which detects a caspase-cleaved cytokeratin-18 (CK-18) fragment and thereby apoptotic ce

54 helial cell markers pan-cytokeratin (Pan-K), cytokeratin-18 (K-18), and occludin.

55 Total and caspase-cleaved cytokeratin-18 (M65 and M30) measured at admission and s

56 mined by alanine aminotransaminase [ALT] and cytokeratin-18 [CK-18]).

57 ch as increased expression of E-Cadherin and cytokeratin-18 and decreased expression of Snail.

58 2-derived peptide, alanine aminotransferase, Cytokeratin-18 and homeostasis model of insulin resistan

59 Colonies of cytokeratin-18 and human albumin-expressing cells were p

60 Levels of M30, a cleavage product of cytokeratin-18 caspase, are significantly increased in s

61 itative Insulin-Sensitivity Check Index, and cytokeratin-18 correlated with NASH.

62 lesterol and adiponectin concentrations, and cytokeratin-18 fragment elevation.

63 rum levels of M30 and M65 antigen (the total cytokeratin-18 fragment, a marker of apoptosis and necro

64 3 +/- 1.5 vs. 1.7 +/- 1.4; P = 0.004), serum cytokeratin-18 fragments (283 vs. 404 U/L; P < 0.001) an

65 Plasma levels of cytokeratin-18 fragments are reliable noninvasive marker

66 labeling-positive nuclei and accumulation of cytokeratin-18 fragments in the liver, was independent o

67 cytokines, markers of hepatocyte apoptosis (cytokeratin-18 fragments), and hepatic fibrogenesis (hya

68 ed low-density lipoproteins, adipokines, and cytokeratin-18 fragments, and an oral glucose tolerance

69 Cytokeratin-18 fragments, controlled attenuation paramet

70 ment of plasma lipoproteins, adipokines, and cytokeratin-18 fragments.

71 ment of plasma lipoproteins, adipokines, and cytokeratin-18 fragments.

72 ling-positive cells, caspase-3 activity, and cytokeratin-18 staining in the liver.

73 cirrhosis contained hepatocyte-derived MPs (cytokeratin-18(+)), whereas plasma from controls did not

74 tested M65 and M30 (circulating fragments of cytokeratin-18) and their respective fraction carried by

75 ll as the epithelial markers pancytokeratin, cytokeratin-18, and occludin, but not mesenchymal (CD44,

76 umin, alpha-fetoprotein, cytochrome P4502E1, cytokeratin-18, type-1 collagen, transforming growth fac

77 of persistent nodules and all HCCs expressed cytokeratin 19 (CK19), whereas 14% of remodeling nodules

78 roteins used clinically for staging disease (cytokeratin 19 [CK19]), identifying cancer stem cells (e

79 and expressed the biliary epithelial markers cytokeratin 19 and carbonic anhydrase IV.

80 n were evaluated by immunohistochemistry for cytokeratin 19 and Ki-67.

81 mine the threshold levels of mammaglobin and cytokeratin 19 correlating with metastasis greater than

82 001) and with the progenitor subtype of HCC (cytokeratin 19 expression, P = 0.031).

83 uamous cell carcinoma antigen (P = .03), and cytokeratin 19 fragment antigen 21-1 (P = .01) were mark

84 Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomarker signature was associa

85 els of epithelial cell adhesion molecule and cytokeratin 19 gene messenger RNAs.

86 2 and hepatic nuclear factor-4alpha, but not cytokeratin 19 or carbonic anhydrase IV.

87 f sex determining region Y-box (SOX)9(+) and cytokeratin 19(+) cells but fewer features of hepatocyte

88 mpression cytology (PAS, cytokeratin 12, and cytokeratin 19) staining were performed in the central c

89 (Col1A1), matrix metalloproteinase 2 (Mmp2), cytokeratin 19, alpha-smooth muscle actin (alpha-SMA), c

90 (7 days in culture) express cytokeratin 18, cytokeratin 19, and vimentin.

91 nce of known stem/progenitor markers such as cytokeratin 19, c-Kit, EpCAM, and activated Wnt-beta-cat

92 sociated with cholangiocyte differentiation (cytokeratin 19, connexin 43, integrin beta4, and gamma-g

93 tures and immunohistochemical markers (PD-1, cytokeratin 19, glutamine synthetase, and beta-catenin e

94 s expressed cholangiocyte markers, including cytokeratin 19, integrin beta4, and aquaporin-1, but not

95 reactive for cytokeratin 18 and negative for cytokeratin 19, vimentin, and alpha-smooth muscle actin

96 ibroblastic RPE (35 days in culture) express cytokeratin 19, vimentin, and alphaSMA.

97 Cytokeratin 19-, A6- and alpha-fetoprotein-positive cell

98 hat increased LC3B was located mainly in the cytokeratin 19-labeled ductular reaction (DR) in human c

99 Cytokeratin 19-positive cells are detected surrounding t

100 naling occupying an alpha-fetoprotein (AFP)+/cytokeratin-19 (CK-19)-positive progenitor cell niche fo

101 (DCAMKL-1), Lgr5, CD133, alpha-fetoprotein, cytokeratin-19 (CK19), Lin28, and c-Myc.

102 ons positive for the progenitor cell marker, cytokeratin-19 (Krt-19) and characterized by a higher pr

103 IBDM was detected by cytokeratin-19 expression and proliferation by Ki-67 imm

104 We determined whether cytokeratin-19 positive (K19(+)) cholangiocytes give ris

105 gon, and somatostatin, as well as peripheral cytokeratin-19 staining.

106 Rat ED14 FLSPC are alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19

107 +)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19(-) and contain all of the normal liver re

108 epithelial marker E-CADHERIN, biliary marker CYTOKERATIN-19, and mesenchymal markers VIMENTIN and alp

109 positive for the stem/progenitor cell marker cytokeratin-19, indicating that several HCC-associated a

110 ssical oval cell markers (alpha-fetoprotein, cytokeratin-19, OV-1 antigen, a6 integrin, and connexin

111 In vivo, the DDC-stimulated number of cytokeratin-19-positive cells in the liver of wild-type

112 e NRF2 pathway accompanied the regression of cytokeratin-19-positive nodules, suggesting that activat

113 igen, epithelial cell adhesion molecule, and cytokeratin-19.

114 f MCC was confirmed by staining positive for cytokeratin 20 (CK20) and synaptophysin.

115 al cytoplasmic stain than the gold standard, cytokeratin 20.

116 owed a higher proliferation rate and greater cytokeratin 3(CK3) expression, indicating that this newl

117 nitiating marker CD44, the progenitor marker cytokeratin 5 (CK5) and are more resistant to standard e

118 is positive for the early epithelial marker cytokeratin 5 (CK5) and the chemokine receptor CXCR4.

119 n of de-differentiated cell markers CD44 and cytokeratin 5 (CK5), lose luminal markers ER and PR, and

120 ve breast cancers contain a subpopulation of cytokeratin 5 (CK5)-expressing cells that are therapy re

121 have discovered that a previously described cytokeratin 5 (K5)-Cre gene construct is expressed in ea

122 tch signalling to activate the DeltaNp63 and cytokeratin 5 program, and subsequent Notch blockade pro

123 ivate a DeltaNp63 (a p63 splice variant) and cytokeratin 5 remodelling program after influenza or ble

124 roid sulfatase), and "proliferation factor" (cytokeratin 5, cytokeratin 5/6, epidermal growth factor

125 ontain increased numbers of p63/AR-positive, cytokeratin 5-negative basal cells compared with WT or A

126 The tumors appear to arise from the cytokeratin 5-positive basal cell compartment.

127 ptor and ERBB2 expression, and expression of cytokeratin 5.

128 s, although none expressed the basal marker, cytokeratin 5.

129 ology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44(-) cancer cells resem

130 uclear hormone receptor and HER2 negativity, cytokeratin 5/6 and vimentin expression, and stem cell e

131 or PR+, HER2+), basal-like (ER-, PR-, HER2-, cytokeratin 5/6 positive, and/or HER1+), HER2+/ER- (ER-,

132 acterised by staining for basal markers (ie, cytokeratin 5/6).

133 c breast cancers expressing the basal marker cytokeratin 5/6, and age- and grade-matched controls, fo

134 n epidermal growth factor receptor 2 (HER2), cytokeratin 5/6, epidermal growth factor receptor, and K

135 , and "proliferation factor" (cytokeratin 5, cytokeratin 5/6, epidermal growth factor receptor, P53).

136 n of basal cells expressing Trp-63 (p63) and cytokeratins 5 (Krt5) and Krt14.

137 uminal breast cancer, progesterone induces a cytokeratin-5 (CK5)-positive basal cell-like population.

138 a-negative cancer cells expressing the basal cytokeratin-5 (CK5).

139 Runx1, Runx3, and cytokeratin-5 expression increased significantly in rege

140 e putative epithelial progenitor cell marker cytokeratin-5.

141 They ultimately differentiate into the cytokeratin 6-positive (K6) inner bulge cells in telogen

142 Knockdown of cytokeratin 6A markedly reduced the bactericidal activit

143 rich C-terminal fragments derived from human cytokeratin 6A were identified in bactericidal lysate fr

144 the unexpected role of a structural protein, cytokeratin 6A, in this process.

145 Two cytokeratin 7 (CK7) samples with a molecular weight rang

146 cystic disease fluid protein-15 (GCDFP-15), cytokeratin 7 (CK7), and smooth muscle actin (SMA).

147 xpressed markers of cholangiocytes including cytokeratin 7 and osteopontin, and the transcription fac

148 glands, apoptotic expression decreased while cytokeratin 7 remained positive.

149 8.18, proximal tubular CD10, distal tubular cytokeratin 7, and endothelial von Willebrand factor mar

150 7 eyes were stained with hematoxylin-eosin, cytokeratin 7, cytokeratin AE1/3, smooth muscle actin, v

151 Cytokeratin 7, EMA, and CD68 were found to be useful imm

152 all biopsy samples were stained positive for Cytokeratin 7, SOX2, Nestin, Vimentin, and CD44.

153 plement 4d (C4d) and for biliary damage with cytokeratin 7.

154 colocalization of a predictive lumen marker, cytokeratin 7.

155 A classic cytokeratin 7/20 staining pattern was present in 23 case

156 in and eosin and by immunohistochemistry for cytokeratins 7 and 20, and Chromogranin A-proteins which

157 ssed intracellular and cell-surface proteins cytokeratin-7 (CK7) and fibroblast growth factor recepto

158 The DR was evaluated by cytokeratin-7 immunohistochemistry in liver biopsies, st

159 ellate cell activation were assessed by anti-cytokeratin-7, anti-glutamine synthetase (GS), anti-cyto

160 tion of the secreted plasminogen activators (cytokeratin 8 and alpha-enolase).

161 of basal (p63, cytokeratin 14) and luminal (cytokeratin 8 and androgen receptor) epithelial cells, a

162 artially rescued Twist1-silenced ERalpha and cytokeratin 8 expression and reduced Twist1-induced inte

163 IL-8 by targeting its 3' UTR, and inhibited cytokeratin 8 via the cell cycle control protein cyclin

164 c cells coexpress luminal epithelium markers cytokeratin 8, androgen receptor, and neuroendocrine mar

165 ased placental glutathione S-transferase and cytokeratin 8-18 activity; starting at 12 wk).

166 pithelial regeneration propose that distinct cytokeratin 8-expressing progenitor cells, arising from

167 In contrast, the cytokeratin 8-positive mammary cell population with prog

168 were visualized and measured with the aid of cytokeratin 8.

169 and by the specific expression of epithelial cytokeratin 8.18, proximal tubular CD10, distal tubular

170 approximately 9 microm in diameter, express cytokeratins 8, 18, and 19, CD133/1, telomerase, CD44H,

171 of several cytoskeletal proteins, including cytokeratins 8, 18, and 19.

172 d found to be CD45 negative and positive for cytokeratins 8, 18, and/or 19 and 4',6-diamidino-2-pheny

173 adhesions and a reduction in E-cadherin and cytokeratins 8/18 and 19.

174 Expression of epithelial markers including cytokeratin-8, E-cadherin, and prosurfactant protein B d

175 ified, in addition to novel genes, including cytokeratins, adhesion molecules, and extracellular matr

176 ained with hematoxylin-eosin, cytokeratin 7, cytokeratin AE1/3, smooth muscle actin, vimentin, and CD

177 l carcinomas positive for alpha-fetoprotein, cytokeratin AE1/AE3, and CD30.

178 istochemical analysis revealed expression of cytokeratin AE1/AE3, CD31, ERG, and FLI-1, with focal an

179 for OM using immunohistochemistry (IHC) for cytokeratin (AE1/AE3) and real-time reverse transcriptas

180 rapid growth, with the expression of biliary cytokeratins, alpha-fetoprotein, and c-Met by FIHC.

181 Coexpression of cytokeratin and human chromosome was observed at 7 and,

182 ochemical staining for tumor markers and for cytokeratin and mucin proteins were used to classify IPN

183 inal, and six oncocytic subtypes; results of cytokeratin and mucin staining were similar to those of

184 large cuboidal cells that were positive for cytokeratin and other markers characteristic of invasive

185 ibodies paired with immunohistochemistry for cytokeratin and surfactant identified pneumocytes and ep

186 nt proteins, we examined the contribution of cytokeratin and vimentin filaments to tumor cell microte

187 notype characterized by immunoreactivity for cytokeratins and endothelial markers.

188 emistry for human-specific breast epithelial cytokeratins and human-specific milk proteins in impregn

189 tive for DeltaNp63 and high molecular weight cytokeratins and negative for low molecular weight cytok

190 ificant underexpression in tumor tissue were cytokeratins and other cytoskeletal components.

191 tive for DeltaNp63 and high molecular weight cytokeratins and positive for low molecular weight cytok

192 by immunohistochemistry using antibodies to cytokeratins and, if positive, prostate-specific antigen

193 ally, in both cases, lesions had epithelial (cytokeratin(+)) and stromal (vimentin/CD10(+)) cell comp

194 children were immunostained for epithelial (cytokeratin) and mesenchymal (vimentin) EMT biomarkers,

195 ction (RET), Dolichos biflorus lectin, EndoA cytokeratin, and aquaporin 2.

196 and partial retention of RPE markers (MITF, cytokeratin, and CRALBP).

197 re likely to induce the expression of simple cytokeratins as has been shown for SV40 in other nonepit

198 of ERK1/2 similarly decreases the basal-like cytokeratins as well as migration.

199 cells were detected by an immunocytochemical cytokeratin assay in preoperatively taken bone marrow as

200 Combined, these data reveal a GABRP-ERK1/2-cytokeratin axis that maintains the migratory phenotype

201 nts (78%) had epithelial CTCs that expressed cytokeratin but not CD45.

202 An intermediate filament cytokeratin "cage" was not observed around KD ICI, makin

203 pericytic cells was lower in the presence of cytokeratin(+) cells in bone marrow.

204 Similar to the presence of cytokeratin(+) cells in the bone marrow, this MSC subpop

205 using basic histology and immunostaining for cytokeratin (CK) 10 and CK13.

206 ls were further identified by costaining for cytokeratin (CK) 19, a biliary marker, or OV6, a hepatic

207 pCAM), neural cell adhesion molecule (NCAM), cytokeratin (CK) 19, albumin +/-, and are negative for a

208 tive" cancers lack steroid receptors but are cytokeratin (CK) 5-positive and require chemotherapy.

209 tissue-and differentiation-specific markers, cytokeratin (CK) 5/6, 13, and 14, to detect presence or

210 LT levels, AST levels, and caspase-3-cleaved cytokeratin (CK)-18 fragments at week 4 were assessed by

211 ession of epithelial markers (E-cadherin and cytokeratin (CK)-18) and an increased expression of mese

212 pindle-like morphology and expressing CD133, cytokeratin (CK)7, CK19, procollagen-alpha1(I), and Snai

213 Immunohistochemical (IHC) staining for cytokeratins (CK) is common practice in evaluating senti

214 tiation markers such as involucrin (IVL) and cytokeratin CK13 in a CSL-dependent fashion.

215 identify by immunohistochemical staining for cytokeratin CK5/6 or CK14 the basal-like subgroup in a s

216 oid cells of MECs were strongly positive for cytokeratin CK5/6, CK34betaE12, and P63; whereas negativ

217 They also express basal cytokeratins CK5 and CK14, have an elevated frequency of

218 cell surface marker EpCAM and intracellular cytokeratins (CKs) for isolation and identification, res

219 These cells stained positive for cytokeratin, confirming their epithelial origin, and als

220 cular endothelial-cadherin (VE-cadherin) and cytokeratins consistent with vasculogenic mimicry (VM),

221 xpress uroplakin II and low molecular weight cytokeratins, consistent with an umbrella cell phenotype

222 ar-weight cytokeratin, high-molecular-weight cytokeratin, cyclo-oxygenase-2, EMA, HER2, matrix metall

223 The absence of major cytokeratin derangements in the squamous papillomas may

224 h as beta-defensins, the cathelicidin LL-37, cytokeratin-derived antimicrobial peptides, and RNase7.

225 ments coaligned with microtentacles, whereas cytokeratin did not.

226 nhanced expression of E-cadherin, epithelial cytokeratins (e.g., CK-19), and tight junction proteins

227 specimens were characterized for epithelial (cytokeratins, E-cadherin) and mesenchymal (vimentin, N-c

228 on marker), anti-CD68 (macrophage), and anti-cytokeratin (epithelial marker).

229 recurrence, those with vimentin-positive and cytokeratin-expressing CTCs had decreased median time to

230 d extension correlated strongly with loss of cytokeratin expression and up-regulation of vimentin, as

231 growth and expansion as determined by human cytokeratin expression.

232 Keratin 19 is a member of the cytokeratin family that is critical for maintenance of c

233 l peptide that redirects keratin 10 from the cytokeratin filament network to the nucleolus.

234 actin or actin-associated proteins, although cytokeratin filaments and dynein anchor certain RNAs.

235 e disruption of actin, tubulin, vimentin, or cytokeratin filaments, suggesting that membrane fusion w

236 omarkers, hepatocyte growth factor (HGF) and cytokeratin fragment 18, in 954 hematopoietic cell trans

237 D from non-GVHD diarrhea better than HGF and cytokeratin fragment 18.

238 ubstrate and used for immobilization of anti-cytokeratin fragment-21-1 (anti-Cyfra-21-1) for the elec

239 These data suggest that epithelial cytokeratins function as endogenous antimicrobial peptid

240 n 6 (KRT6) family located within the type II cytokeratin gene cluster on chromosome 12 of humans and

241 Here we report that epithelial cytokeratins have innate defense properties because they

242 L2, caspase-9, CD34MVD, low-molecular-weight cytokeratin, high-molecular-weight cytokeratin, cyclo-ox

243 subjected to immunofluorescence for ICI and cytokeratin, high-throughput sequencing, and transmissio

244 sitive for CD34 and HHF-35, but negative for cytokeratin, HMB-45 and Melan-A.

245 entiation (E-cadherin, high molecular weight cytokeratins (Hmw CK) and CK5, vimentin) and lineage dif

246 sosulfan blue dye) and ultrastaging with pan-cytokeratin IHC in conjunction with standard histopathol

247 d an image-based computational method on pan-cytokeratin IHC stainings to quantify tumor fragmentatio

248 LNs (N0) were examined for OM, diagnosed by cytokeratin immunohistochemistry (IHC).

249 and eosin (H&E) negative LNs (N0) using pan-cytokeratin immunohistochemistry (pan-CK-IHC) is unknown

250 pN0 LNs were collected and assessed by using cytokeratin immunostaining in two serial histology secti

251 taining showed similar staining patterns for cytokeratins in large cell acanthoma and normal conjunct

252 e immunohistochemical analysis of a range of cytokeratins in normal conjunctival epithelium, normal c

253 Ig-bound proteins yielding a predominance of cytokeratins, including several associated with a mesenc

254 d Eomes, and also the trophectoderm-specific cytokeratin intermediate filament, recognised by Troma1,

255 Positive staining for either cytokeratin is very significantly associated with that f

256 Here, in analyzing the expression of basal cytokeratin (K) 14 in the secretory complex, we discover

257 ative LSC markers ABCG2, DeltaNp63alpha, and cytokeratin (K)14 were significantly higher in the SSEA4

258 a novel transgenic (Tg) mouse model, using a cytokeratin K14 promoter to drive expression of the E6 a

259 MAML1 was targeted to the mouse esophagus by cytokeratin K14 promoter-driven Cre (K14Cre) recombinati

260 on ( approximately 50%) stained for both pan-cytokeratin (KRT) markers and the common leukocyte marke

261 usions and expression of the BLBC-associated cytokeratins, KRT5, KRT6B, KRT14, and KRT17.

262 These results show that the basal cytokeratin-like carcinomas contain many of the MIPs and

263 of a combination of cell surface receptors, cytokeratin markers, drug transporters and the efficient

264 ssociated vesicles are enmeshed in an apical cytokeratin meshwork and that Rab11a likely acts upstrea

265 determined by immunocytochemistry using pan-cytokeratin monoclonal antibodies.

266 No patients had cytokeratin-negative and vimentin-positive CTCs.

267 omeric probe showed that positive cells were cytokeratin-negative at 24 hours.

268 uster differentiation-44 (CD44)-positive but cytokeratin-negative, unlike the case in other regenerat

269 identifying HBEC as CD45 negative, EpCAM/pan-cytokeratin (pan-CK) double-positive population after ex

270 (Ccsp), and the epithelial cell markers pan-cytokeratin (Pan-K), cytokeratin-18 (K-18), and occludin

271 The papillomas displayed a normal cytokeratin pattern but exhibited a higher than normal P

272 ratins and positive for low molecular weight cytokeratins) phenotypes, with DeltaNp63 expression asso

273 r phagocytes in human gastric mucosa contain cytokeratin-positive and TUNEL-positive AEC material, in

274 aining and the loss of high molecular weight cytokeratin-positive basal epithelial cells.

275 The presence of cytokeratin-positive CTCs (P < 0.01), but not mesenchyma

276 The presence of cytokeratin-positive CTCs remained a significant indepen

277 In the TI, alpha8 integrin was localized to cytokeratin-positive epithelial cells and to interstitia

278 nchymal markers, including vimentin (VIM) in cytokeratin-positive epithelial cells metalloproteinase

279 factor Twist1 induced rapid dissemination of cytokeratin-positive epithelial cells.

280 2 to vimentin-positive decidual cells versus cytokeratin-positive interstitial trophoblasts.

281 PVR membranes and partially colocalized with cytokeratin-positive RPE cells.

282 against networks involving BRCA1, TP53, and cytokeratin proteins associated with a mesenchymal/basal

283 itial trophoblast (IT) markers, vimentin and cytokeratin, respectively.

284 to flattened, polygonal cells and expressed cytokeratin, RPE65, and microphthalmia transcription fac

285 cinoma, where lineage tracing indicates that Cytokeratin-Synaptophysin dual positive cells arise from

286 Higher percentages of Cytokeratin-Synaptophysin dual positive tumor cells corr

287 and express pRb, the epithelial cell marker cytokeratin that is expressed in the retinal pigmented e

288 n of cytoskeletal elements such as actin and cytokeratin through a calcium-dependent process that has

289 fluorescence-labeled antibodies against pan-cytokeratin through flow cytometry.

290 quantitative analysis (AQUA) method; we used cytokeratin to define pixels as breast cancer (tumor mas

291 ing a multiplexed assay for ALDH1, CD44, and cytokeratin to measure the coexpression of these protein

292 ns and structures, including those involving cytokeratins, topoisomerase-2-alpha, and post-translatio

293 ratins and negative for low molecular weight cytokeratins) versus luminal-like (negative for DeltaNp6

294 e using commercially available antibodies to cytokeratin, vimentin, and CD45.

295 tection of CTCs expressing both vimentin and cytokeratin was predictive of recurrence (P = 0.01).

296 The expression of claudins and cytokeratins was heterogeneous.

297 Fibronectin and cytokeratin were accumulated along the stroma-to-stroma

298 taining and immunohistochemical staining for cytokeratin were used at two widely spaced additional ti

299 tion markers prosurfactant protein-C and pan-cytokeratins were passed to the opposing daughter cell,

300 (P = .20), the mean proliferation index with cytokeratin wide-spectrum was 2.55 vs 1.13 (P = .06), an